Petros Pharmaceuticals Statistics
Share Statistics
Petros Pharmaceuticals has 2.14M
shares outstanding. The number of shares has increased by 0.06%
in one year.
| Shares Outstanding | 2.14M |
| Shares Change (YoY) | 0.06% |
| Shares Change (QoQ) | -0.01% |
| Owned by Institutions (%) | 3.35% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | n/a |
| FTD / Avg. Volume | n/a |
Short Selling Information
The latest short interest is 12.35M, so 576.7% of the outstanding
shares have been sold short.
| Short Interest | 12.35M |
| Short % of Shares Out | 576.7% |
| Short % of Float | 600% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -5.52 and the forward
PE ratio is -0.14.
Petros Pharmaceuticals's PEG ratio is
0.06.
| PE Ratio | -5.52 |
| Forward PE | -0.14 |
| PS Ratio | 15.46 |
| Forward PS | n/a |
| PB Ratio | -10.59 |
| P/FCF Ratio | -30.09 |
| PEG Ratio | 0.06 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Petros Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.4,
with a Debt / Equity ratio of -0.99.
| Current Ratio | 0.4 |
| Quick Ratio | 0.33 |
| Debt / Equity | -0.99 |
| Debt / EBITDA | -0.68 |
| Debt / FCF | -2.81 |
| Interest Coverage | -31.52 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $284,002.39 |
| Profits Per Employee | $-795,488.33 |
| Employee Count | 18 |
| Asset Turnover | 0.48 |
| Inventory Turnover | 0.9 |
Taxes
| Income Tax | 26.78B |
| Effective Tax Rate | -187046.81% |
Stock Price Statistics
The stock price has increased by null% in the
last 52 weeks. The beta is 2.2, so Petros Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 2.2 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 1.3 |
| 200-Day Moving Average | 6.18 |
| Relative Strength Index (RSI) | 29.04 |
| Average Volume (20 Days) | n/a |
Income Statement
In the last 12 months, Petros Pharmaceuticals had revenue of 5.11M
and earned -14.32M
in profits. Earnings per share was -0.02.
| Revenue | 5.11M |
| Gross Profit | 3.9M |
| Operating Income | -17.68M |
| Net Income | -14.32M |
| EBITDA | -10.81M |
| EBIT | -13.76M |
| Earnings Per Share (EPS) | -0.02 |
Full Income StatementBalance Sheet
The company has 3.71M in cash and 7.39M in
debt, giving a net cash position of -3.68M.
| Cash & Cash Equivalents | 3.71M |
| Total Debt | 7.39M |
| Net Cash | -3.68M |
| Retained Earnings | -113.21M |
| Total Assets | 17.61M |
| Working Capital | -12.67M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -2.6M
and capital expenditures -24.59K, giving a free cash flow of -2.63M.
| Operating Cash Flow | -2.6M |
| Capital Expenditures | -24.59K |
| Free Cash Flow | -2.63M |
| FCF Per Share | -0.33 |
Full Cash Flow StatementMargins
Gross margin is 76.28%, with operating and profit margins of -345.84% and -280.1%.
| Gross Margin | 76.28% |
| Operating Margin | -345.84% |
| Pretax Margin | -280.1% |
| Profit Margin | -280.1% |
| EBITDA Margin | -211.54% |
| EBIT Margin | -345.84% |
| FCF Margin | -51.4% |
